CHILDREN'S ADVIL-FLAVORED
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CHILDREN'S ADVIL-FLAVORED (CHILDREN'S ADVIL-FLAVORED).
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, resulting in antipyretic, analgesic, and anti-inflammatory effects.
| Metabolism | Hepatic metabolism primarily via CYP2C9, with minor contributions from CYP2C8 and CYP2C19. Conjugation with glucuronic acid and renal excretion of inactive metabolites. |
| Excretion | Renal excretion of conjugated metabolites (75-80% as glucuronide and sulfate conjugates, <10% as unchanged drug); biliary/fecal elimination accounts for <5%. |
| Half-life | 2-4 hours in children; prolonged in neonates (up to 30 hours) and hepatic impairment. |
| Protein binding | 90-99% bound to albumin at therapeutic concentrations. |
| Volume of Distribution | 0.1-0.2 L/kg; low Vd consistent with high protein binding and limited tissue distribution. |
| Bioavailability | Oral: 85-95% (suspension); rectal: 70-80%. |
| Onset of Action | Oral: 30-60 minutes for antipyresis; 1 hour for analgesia. |
| Duration of Action | 4-6 hours (antipyretic and analgesic effects). |
| Molecular Weight | 206.29 |
200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day without prescription, up to 3200 mg/day under medical supervision.
| Dosage form | SUSPENSION |
| Renal impairment | CrCl 30-60 mL/min: reduce dose by 25% and avoid if CrCl <30 mL/min; for severe renal impairment (CrCl <30 mL/min) or dialysis, contraindicated. |
| Liver impairment | Child-Pugh Class A (mild): no adjustment; Child-Pugh Class B (moderate): start at lowest effective dose, reduce total daily dose by 50%; Child-Pugh Class C (severe): avoid use. |
| Pediatric use | Infants 6-23 months: 50 mg; children 2-3 years (12-14 kg): 100 mg; 4-5 years (15-21 kg): 150 mg; 6-8 years (22-27 kg): 200 mg; 9-10 years (28-33 kg): 250 mg; 11 years (34-40 kg): 300 mg; all doses orally every 6-8 hours, maximum 4 doses per day; based on ibuprofen 5-10 mg/kg/dose, max 40 mg/kg/day. |
| Geriatric use | Start at lowest effective dose (200 mg every 6-8 hours), increase cautiously; monitor renal function and GI bleeding risk; maximum 1200 mg/day without prescription. |
| 1st trimester | Avoid use during first trimester; associated with increased risk of miscarriage and congenital malformations (e.g., cardiac defects, gastroschisis) based on observational studies. NSAIDs are not recommended unless clearly necessary. |
| 2nd trimester | Use with caution; may cause oligohydramnios and fetal renal impairment. Avoid prolonged use. Ibuprofen is preferred over other NSAIDs if needed, but consider paracetamol for short-term pain/fever. |
| 3rd trimester | Contraindicated during third trimester due to risk of premature closure of ductus arteriosus, oligohydramnios, fetal renal toxicity, and inhibition of labor. NSAIDs should be avoided after 30 weeks gestation. |
Clinical note
Comprehensive clinical and safety monograph for CHILDREN'S ADVIL-FLAVORED (CHILDREN'S ADVIL-FLAVORED).
| Placental transfer | Ibuprofen readily crosses the placenta with cord blood concentrations ranging from 50-100% of maternal plasma levels, depending on dose and timing. Fetal exposure is substantial, especially in third trimester. |
| Breastfeeding |
■ FDA Black Box Warning
Cardiovascular thrombotic events: NSAIDs increase risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. Risk increases with duration of use and in patients with cardiovascular risk factors. Contraindicated for treatment of perioperative pain in coronary artery bypass graft (CABG) surgery.
| Serious Effects |
Hypersensitivity to ibuprofen or any componentHistory of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDsActive or history of recurrent peptic ulcer disease or gastrointestinal bleeding (including perforation)Severe hepatic impairment (Child-Pugh class C)Severe renal impairment (eGFR <30 mL/min/1.73m²)Advanced renal diseaseSevere uncontrolled hypertensionTreatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgeryThird trimester of pregnancy (after 30 weeks gestation) – absolute contraindication for nonsteroidal anti-inflammatory drugsSystemic lupus erythematosus (increased risk of aseptic meningitis)
| Precautions | Cardiovascular thrombotic events; gastrointestinal bleeding, ulceration, and perforation; increased risk of serious GI adverse events in the elderly; renal toxicity (especially in patients with impaired renal function, heart failure, liver dysfunction, those taking diuretics or ACE inhibitors); anaphylactoid reactions; skin reactions (Stevens-Johnson syndrome); use in pregnancy (avoid during third trimester). |
Loading safety data…
| Ibuprofen is excreted into breast milk in very low concentrations (estimated 0.6-0.9% of maternal dose). It is considered compatible with breastfeeding. Use lowest effective dose for shortest duration. No adverse effects in infants reported in typical therapeutic doses. |
| Lactation Rating | L1 (Safe) - Compatible with breastfeeding. Ibuprofen is a preferred analgesic/antipyretic during lactation. |
| Teratogenic Risk | Ibuprofen is contraindicated in the third trimester due to risk of premature closure of ductus arteriosus and oligohydramnios. In first and second trimesters, use only if clearly needed; risk of miscarriage and specific malformations (e.g., cardiac defects, gastroschisis) is increased, especially with prolonged use. |
| Fetal Monitoring | Monitor for signs of ductus arteriosus constriction (fetal echocardiography) and oligohydramnios (amniotic fluid index) if used beyond 20 weeks; assess maternal renal function and bleeding risk. |
| Fertility Effects | Reversible inhibition of ovulation and potential delay in conception due to luteal phase defects and interference with prostaglandin synthesis. Effects are dose-dependent and resolve upon discontinuation. |
| Food/Dietary | Take with food or milk to reduce GI upset. Avoid concurrent alcohol consumption due to increased GI bleeding risk. No other significant food interactions. |
| Clinical Pearls | For febrile children, dose by weight (5-10 mg/kg/dose) not age; avoid use in varicella due to risk of Reye's syndrome; contraindicated in children with active peptic ulcer disease or GI bleeding; use lowest effective dose for shortest duration; monitor renal function in prolonged use. |
| Patient Advice | Always use the provided dosing syringe to measure exactly, not household spoons. · Do not give more than 5 doses in 24 hours. · Space doses at least 4 hours apart. · Do not combine with other products containing ibuprofen or other NSAIDs. · Discontinue and contact doctor if symptoms worsen or new symptoms appear. · Store at room temperature away from moisture. |